首页> 外文期刊>Molecular and Cellular Endocrinology >Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines
【24h】

Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines

机译:吉西他滨单独或与米托坦合用对肾上腺皮质癌细胞系的细胞毒活性

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

We aimed at investigating in vitro the cytotoxic activity (determined using WST-1, apoptosis and cell cycle assays) of gemcitabine, alone or in combination with mitotane, in mitotane-sensitive H295R and mitotane-insensitive SW-13 cells. Results of these experiments were compared with drug-induced modulation of RRM1 gene, the specific target of gemcitabine. In H295R cells, mitotane and gemcitabine combinations showed antagonistic effects and interfered with the gemcitabine-mediated inhibition of the S phase of the cell cycle. By contrast, in SW-13 cells, except when mitotane was sequentially administered prior to gemcitabine, the combination of the two drugs was synergistic. Such opposite effects were associated with opposite expression profiles of the target gene, with significant up-modulation in H295R but not in SW-13 under gemcitabine and mitotane combination treatment.
机译:我们旨在研究吉西他滨单独或与米托坦合用对米托坦敏感的H295R和不对米托坦敏感的SW-13细胞的细胞毒性活性(由WST-1,凋亡和细胞周期测定确定)。将这些实验的结果与吉西他滨的特异性靶标RRM1基因的药物诱导调节进行了比较。在H295R细胞中,米线烷和吉西他滨的组合表现出拮抗作用,并干扰了吉西他滨介导的细胞周期S期抑制。相比之下,在SW-13细胞中,除了在吉西他滨之前先后施用米托坦外,两种药物的组合具有协同作用。这种相反的作用与靶基因的相反表达谱有关,在吉西他滨和米线烷联合处理下,H295R中的显着上调但在SW-13中没有显着上调。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号